Non-medical Use (NMU) Data Report Services

SOL #: 75F40126R00013Solicitation

Overview

Buyer

Health And Human Services
Food And Drug Administration
FDA OFFICE OF ACQ GRANT SVCS
Rockville, MD, 20852, United States

Place of Performance

Silver Spring, MD

NAICS

Research and Development in the Social Sciences and Humanities (541720)

PSC

Health R&D Services; Health Care Other; Basic Research (AN41)

Set Aside

No set aside specified

Timeline

1
Posted
Feb 18, 2026
2
Last Updated
Mar 16, 2026
3
Submission Deadline
Mar 19, 2026, 1:00 PM

Qualification Details

Fit reasons
  • NAICS alignment with historical contract wins in similar service areas.
  • Scope strongly matches core technical capabilities and delivery model.
Risks
  • Past performance thresholds may require one additional teaming partner.
  • Potential clarification needed on staffing minimums before bid/no-bid.
Next steps

Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.

Quick Summary

The U.S. Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), Office of Surveillance and Epidemiology (OSE) is soliciting proposals for Non-Medical Use (NMU) Data Report Services. This is a multiple-award Indefinite Delivery Indefinite Quantity (IDIQ) contract aimed at obtaining post-marketing data on the nonmedical use of prescription and over-the-counter drug products, illicit substances, and other emerging regulatory interest substances. The maximum aggregate value for all task orders over the 5-year period is $8,500,000.00. Proposals are due by 9:00 AM Eastern on March 19, 2026.

Purpose & Scope

The primary objective is to inform FDA's pharmaceutical regulatory and oversight efforts, identify emerging substances of concern, and support NMU prevention programs. The surveillance scope includes FDA-approved prescription and OTC drugs, illicit substances, and emerging substances like psychedelics, tianeptine, xylazine, and cannabis.

Key Requirements / Deliverables

  • Task Area 1: Post-Market Surveillance: Provide bi-annual summary reports, ad-hoc reports, and analytical datasets from existing surveillance data, including population-based, de-identified data from individuals entering substance use disorder treatment, with at least ten years of historical data.
  • Task Area 2: Topic-Specific Studies/Analyses: Conduct focused studies or analyses on drug products and emerging substances, potentially leveraging real-world data, internet panel surveys, and qualitative analyses of internet postings.
  • Task Area 3: Project Management: Includes a kick-off meeting, submission of a Project Management Plan and Data Management Plan, and a Quality Assurance Surveillance Plan (QASP). Quarterly teleconferences are required.
  • Deliverables: Task order specific reports (monthly, annual, final project) submitted electronically in Microsoft Word compatible format, compliant with Section 508 accessibility standards.

Contract Details

  • Contract Type: Multiple-Award IDIQ
  • Period of Performance: Anticipated Base Year (Sept 30, 2026 - Sept 29, 2027) with four Option Years, totaling a 5-year ordering period. Task orders may not exceed five years but can extend up to 36 months beyond the IDIQ expiration.
  • Estimated Value: Minimum guarantee of $3,000.00; Maximum aggregate $8,500,000.00.
  • Anticipated Awards: FDA anticipates awarding a maximum of two IDIQ contracts.
  • NAICS Code: 541720 (Research and Development in the Social Sciences and Humanities).
  • Set-Aside: Unrestricted. Small business set-aside options (Small Business, HUBZone, WOSB, EDWOSB, SDVOSB, 8(A)) may be applied at the task order level.

Submission & Evaluation

  • Submission Deadline: March 19, 2026, 9:00 AM Eastern.
  • Questions Deadline: March 5, 2026, 9:00 AM Eastern.
  • Submission Method: Electronically via email to Nam Nguyen (nam.nguyen@fda.hhs.gov).
  • Proposal Format: Proposals must be submitted in two separate volumes: Volume I-Technical and Volume II-Business/Price. Total submission is limited to 50 pages (including coversheets, tables of contents, and appendices).
  • Pricing: The provided Attachment A - Pricing Table must be completed. Offerors must provide loaded labor hour prices for specified labor categories across five ordering periods. Do not adjust pre-set quantities or add labor categories. Other Direct Costs (ODCs) should be incorporated into fully burdened labor rates, with a brief narrative explanation in the pricing volume.
  • Evaluation Criteria: Best value trade-off process. Technical factors (Data Access and Capabilities, Technical Approach and Understanding, Personnel Qualifications, Quality Assurance and Data Management, Past Performance) are more important than Price. Confidence ratings will be used for technical factors.
  • Eligibility: Active registration in SAM.gov is required.

Data & Scope Clarifications

  • FDA prefers standardized self-reported data but will consider other approaches. At a minimum, information on active pharmaceutical ingredient (API) is required.
  • Offerors are expected to independently provide and maintain access to a database of at least 50,000 subjects.
  • FDA anticipates issuing 2-4 task orders over the contract life, with 0-2 ad hoc analytic requests annually.
  • Typical data lag for surveillance analyses ranges from 45 days to 12 months.

People

Points of Contact

Nam NguyenPRIMARY

Files

Files

Download
Download
Download

Versions

Version 4
Solicitation
Posted: Mar 16, 2026
View
Version 3Viewing
Solicitation
Posted: Mar 12, 2026
Version 2
Solicitation
Posted: Mar 11, 2026
View
Version 1
Solicitation
Posted: Feb 18, 2026
View
Non-medical Use (NMU) Data Report Services | GovScope